C1S and cold agglutinin disease: The monoclonal antibody anti-C1s sutimlimab (formerly TNT003/BIVV009) has been proven to have a meaningful effect on hemoglobin levels, hemolysis, and fatigue, both in a pilot study mostly in secondary CAD [75,76] and in a prospective trial in primary CAD (NCT03347422, NCT03347396).